SLS SELLAS Life Sciences Group, Inc.
USHealthcareAs of 2026-07-09 16:00
Why SLS matters now
SELLAS Life Sciences Group, Inc. (SLS) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.51 with -1.82% on the session and $2.51B in market capitalization; recent performance reads 1-month +6.06% and YTD +113.53%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.4M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.5%.
The latest indexable market news headline is "SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.80; recent insider activity includes Stergiou Angelos M. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.93
P/S
0.00
EV/EBITDA
-46.50
DCF Value
$0.63
FCF Yield
-2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.1%
ROA
-25.8%
ROIC
-29.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.4M | $-0.05 |
| Q4 2025 | $0.00 | $-7.7M | $-0.05 |
| FY 2025 | $0.00 | $-26.9M | $-0.25 |
| Q3 2025 | $0.00 | $-6.8M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.80
Target (Median)
$2.80
Target Range
$2.40 - $3.20
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.53
SELLAS Life Sciences Group, Inc. operates as a late-stage biopharmaceutical entity, dedicated to advancing novel cancer immunotherapies for various cancer indications across the United States. Its primary investigational product, galinpepimut-S (GPS), is a cancer immunotherapeutic agent engineered to target Wilms tumor 1. GPS is currently in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 studies for ovarian cancer. Additionally, the company is progressing nelipepimut-S, an immunotherapy aimed at human epidermal growth factor receptor 2, which is undergoing Phase 2b clinical evaluation for early-stage breast cancer. A strategic collaboration with Merck & Co., Inc. is underway to assess GPS in combination with the PD1 blocker pembrolizumab, specifically within a Phase 1/2 clinical trial encompassing up to five distinct cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, SELLAS maintains its corporate headquarters in New York, New York.